Background--Long-term data on durability of currently available transcatheter heart valves are sparse. We sought to assess the incidence of long-term (8-year) structural valve dysfunction and bioprosthetic valve failure in a cohort of patients with transcatheter aortic valve replacement (TAVR) who reached at least 5-year follow-up.
T ranscatheter aortic valve replacement (TAVR) is an established alternative for patients with severe aortic stenosis (AS). 1 On the basis of the favorable outcomes of recent randomized clinical trials conducted in intermediaterisk populations, 2, 3 TAVR is progressively being offered to younger and lower-risk patients. In this particular subset, life expectancy is expected to exceed that of initial candidates to TAVR (ie, elderly and very elderly patients at high or prohibitive surgical risk), which makes the question of longterm prosthesis durability of crucial importance. If transcatheter heart valve (THV) durability up to 5 years is already a well-established reality, with low rates of structural valve dysfunction (SVD) demonstrated in large and methodologically rigorous studies, [4] [5] [6] [7] [8] data on clinical outcomes and THV integrity after 5 years remain extremely scarce. 9 An important challenge when reporting the rates of SVD (and comparing them with those of previous studies) deals with its definition. The few studies reporting on SVD after TAVR used heterogeneous criteria, rendering interstudy comparisons problematic. [5] [6] [7] [8] [9] [10] To address this issue, the European Association of Percutaneous Cardiovascular Interventions (EAPCI), the European Society of Cardiology (ESC), and the European Association for Cardio-Thoracic Surgery (EACTS) recently introduced standardized criteria to define SVD of THV that aim at generating uniformity in data reporting of future studies assessing the long-term durability of TAVR.
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On this background, the aim of this study was to report on the incidence of long-term SVD and bioprosthetic valve failure (BVF), defined according to the new EAPCI-ESC-EACTS criteria, in a cohort of patients with TAVR who reached at least 5-year follow-up.
Methods
Additional data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Patient Population
This study included 288 consecutive patients who underwent TAVR between June 4, 2007 to March 30, 2012 to allow for a follow-up of at least 5 years. All patients received either the self-expanding CoreValve (Medtronic Inc, Minneapolis, MN) or the balloon-expandable Edwards-SAPIEN XT (Edwards Lifesciences, Irvine, CA) THV. The device was delivered through either the transfemoral or the transsubclavian approach.
A multidisciplinary team, including cardiologists (D.G., W.D.), cardio-thoracic surgeons (A.G.), anesthesiologists, geriatricians, and interventional cardiologists (M.B., C.S., C.T.), evaluated all available clinical and imaging data, and a consensus decision was obtained to determine individual eligibility for TAVR. The decision to perform TAVR was conditional on the presence of severe symptomatic AS with contraindications to or high risk for surgical aortic valve replacement, life expectancy of 1 year, and anatomical features suitable for intervention. All patients provided written informed consent for inclusion in the study. Screening investigations were performed in all patients before the procedure, with sizing of the THV performed by using multidetector computed tomography and an integration of echocardiography (transthoracic and/or transesophageal), angiography, and/or simultaneous aortography during balloon valvuloplasty, 12 when multidetector computed tomography was not available. The local institutional review committee approved the study. What Are the Clinical Implications?
Data Collection and Definitions
• It is key that standardized criteria will be applied when reporting transcatheter aortic valve performances at mid-to long-term follow-up.
• If these favorable outcomes will be confirmed in larger series, transcatheter aortic valve replacement could be considered the preferred therapy for patients with severe aortic stenosis.
morphological SVD ("isolated hemodynamic dysfunction"). 
Statistical Analysis
Continuous variables are presented as meanAESD, whereas dichotomous parameters are presented as frequencies and percentages. Survival curves for the outcomes of interest were plotted according to the Kaplan-Meier method (actuarial analysis). SVD and BVF were also reported as cumulative incidence function (actual analysis) to account for the competing risk of death. All estimates are presented with their 95% confidence interval (CI). All analyses were conducted in R (version 3.3.2) equipped with the "cmprsk" and "survival" packages. Data are given as number (percentage). THV indicates transcatheter heart valve. 
Procedural and 30-Day Outcomes
Procedural data are shown in Table 2 . Transfemoral access was used in 283 patients (98.3%); in 5 patients (1.7%) in whom the transfemoral approach was unfeasible, a transsubclavian access was used. The CoreValve prosthesis was implanted in 237 patients (82.3%), whereas the SAPIEN XT THV was used in 48 patients (16.7%). Balloon predilatation was performed in all patients. Valve Academic Research Consortium-2-defined device success was obtained in 240 patients (83.3%). In 2 patients (0.7%), the THV was not deployed because of technical issues, and implantation of 2 THVs was required in 10 patients (3.5%). The 30-day outcomes are listed in Table 3 . Overall, 30-day mortality was 9.0%. Disabling stroke and disabling bleeding were reported in 2.1% and 8.2% of patients, respectively. A permanent pacemaker was implanted in 16.3% of patients, in most cases because of permanent or intermittent thirddegree atrioventricular block.
Long-Term Survival
Clinical follow-up was available in all patients at a median follow-up of 80.7 months. A total of 171 patients died at a median of 60.1 months (interquartile range, 51-72 months). Death was attributed to cardiovascular reasons in 60 patients (35%). Kaplan-Meier survival estimates at 1, 4, and 8 years were 81.9%, 61.0%, and 29.8%, respectively (Figure 1 ). 
THV Durability
Among survivors at 5 years (n=158), the 6.7% of patients potentially suitable for transthoracic echocardiogram assessment were unavailable for follow-up ( Figure 2 ). Information on last available echocardiogram in the patients who died compared with the patients who were still alive at 5, 6, 7, and 8 years (sequentially) is reported in Table 4 . Prosthesis performance during follow-up is depicted in Figure 3 . At discharge, mild and more than mild paravalvular regurgitation were observed in 147 patients (51.0%) and 38 patients (13.2%), respectively. Mean pressure gradients decreased from 53.3AE15.9 mm Hg (pre-TAVR) to 10.5AE4.5 mm Hg (inhospital post-TAVR) (P<0.001). Subsequently, there was a small, not significant, increase in the transaortic gradient throughout follow-up (Figure 3) . BVF was observed in a total of 11 patients (8-year cumulative incidence function: 4.51%; 95% CI, 1.95%-8.76%) (Figures 4 and 5, left panels) . Severe SVD was reported in 7 patients (8-year cumulative incidence function: 2.39%; 95% CI, 0.77%-5.71%) (Figures 4 and 5, right panels) . The survival rates free from BVF and severe SVD at 8 years are 95.4% (95% CI, 91.9%-98.9%) and 97.5% (95% CI, 0.95%-1.00%) ( Figure 5 ). Moderate SVD was found in 13 patients (8-year cumulative incidence function: 5.87%; 95% CI, 3.06%-9.96%). The 30-day landmark analyses for BVF and severe SVD are shown in Figure 6 .
Among the 11 patients meeting criteria for BVF (Table 5 ), 4 had valve-related deaths: 1 patient had aortic annulus rupture after SAPIEN XT implantation (death at day 1), 1 patient died because of left main occlusion after CoreValve deployment (intraprocedural death), and the last 2 patients died at days 37 and 2784 because of acute heart failure (low CoreValve implantation causing severe paravalvular regurgitation). The remaining 7 patients had severe SVD. Of the latter (Figure 7 ), 4 had severe restenosis, 1 had mixed severe stenosis and regurgitation, and 1 experienced valve endocarditis at 2 years, causing severe intraprosthetic aortic regurgitation. Two cases (1 severe restenosis and 1 severe intraprosthetic regurgitation) were effectively treated with redo TAVR, and the other 2 patients were asymptomatic and, therefore, left untreated. Severe SVD caused symptoms in 3 patients, whereas all cases of moderate SVD were found in asymptomatic patients. No other cases of late THV deterioration 
Discussion
TAVR is now considered as a valuable alternative to conventional aortic valve replacement in high-and intermediate-risk patients affected by severe AS. Although many studies have confirmed the durability of TAVR up to 5 years, there is still a paucity of data on the incidence of structural deterioration and valve failure at longer-term follow-up. This analysis adds to the current knowledge of long-term durability and structural integrity of THVs with the following observations: (1) in an elderly population (mean age, 80 years), we showed acceptable long-term outcomes, with an 8-year survival rate of 29.8%; (2) at 8 years, BVF, severe SVD, and moderate SVD, according to the new EAPCI/ESC/EACTS definitions, occurred in only 4.5%, 2.4%, and 5.9% of patients, respectively; (3) and reintervention with redo TAVR was performed successfully in 2 patients (the remaining patients with severe SVD and no symptoms did not need any additional invasive treatment).
As the duration of implanted THVs increases, valve durability and dysfunction become more crucial issues. 15 No significant increases in mean THV gradient or cases of structural valve deterioration were reported during the 5-year follow-up of the PARTNER (Placement of Aortic Transcatheter Valves) I trial. 8 SVD, defined as leaflet thickening ≥3 mm, presence of calcification, and abnormal leaflet motion, was reported in 29 patients (30%). However, SVD was associated with severe stenosis only in 1 patient and with mild stenosis in 7 patients. 8 A key limitation of the previously described studies is the lack of uniform and standardized criteria to define SVD. Recently, a joint consensus statement from the EAPCI, ESC, and EACTS has introduced standardized definitions of SVD and BVF in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves. 11 The scope of the new definition is to introduce consistency in the reporting of longterm durability of both THV and surgical bioprostheses, with focus not only on survival or reoperation, but also on the clinical implications of SVD. The present study is the first reporting on long-term THV performance using such definitions. We were able to obtain >5-year echocardiographic assessment in >90% of patients, and these data confer strength to the present analysis. At 8 years, the incidence of BVF was 4.5%: THV-related death was definite in 4 patients. Remaining cases of BVF were caused by severe SVD, which was reported in a total of 7 patients. Restenosis, with or without concomitant regurgitation, was the most common cause of SVD, being reported in 5 cases as a consequence of calcification and tissue ingrowth. Isolated new intraprosthetic regurgitation was found in 2 patients as a consequence of reduced leaflet mobility (leaflet calcification) or endocarditis. Surgical aortic bioprostheses have shown 10-year freedom from valvular failure in the range of 60% to 90%. Reported rates of SVD requiring reoperation range widely from 6% to 47% by 12 to 20 years after surgical implantation. [16] [17] [18] [19] At 5 years, freedom from structural failure is generally >95%, and although early failure requiring reoperation or leading to mortality has been reported, freedom from reoperation at 5 years is also generally >95%.
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Limitations
The present analysis has some limitations, including the relatively small sample size and its single-center nature. Also, follow-up on echocardiographic data was performed in a "survival cohort," with death possibly exerting a competing risk that may have biased our results. To limit this effect, we reported both actuarial and actual estimates, as recommended by the EAPCI/ESC/EACTS consensus statement.
Conclusions
In an aged population of patients with symptomatic severe AS treated with first-generation bioprostheses, TAVR was associated with a survival rate of 29.8% but low rates of BVF and SVD at 8 years.
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